IM Cannabis (IMCC) Return on Capital Employed (2021 - 2026)
IM Cannabis' (IMCC) quarterly Return on Capital Employed came in at 4988.38% in Q1 2026, up 643132.0% year-on-year from N/an in Q1 2025, and up 1959.71% quarter-over-quarter from 268.23% in Q4 2025.
IM Cannabis (IMCC) Return on Capital Employed (2021 - 2026) Analysis & Trends
IM Cannabis' Return on Capital Employed history runs 6 years deep, the most recent figure standing at 4988.38% for Q1 2026.
- On a quarterly basis, Return on Capital Employed rose 643132.0% year-over-year to 4988.38% in Q1 2026; TTM through Mar 2026 was 4988.38%, a 643132.0% increase from a year earlier, with the FY2025 full-year figure at 636.73%, down 52834.0% from the prior year.
- Return on Capital Employed grew to 4988.38% in Q1 2026 per IMCC's latest filing, from 268.23% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 4988.38% in Q1 2026 and bottomed at 1442.93% in Q1 2025.
- The 5-year median for Return on Capital Employed is 268.23% (2025), against an average of 30.96%.
- Across the five-year window, Return on Capital Employed sank 131981 bps in 2025 and soared 643132 bps in 2026, its largest moves.
- Year by year, Return on Capital Employed stood at 298.25% in 2022, then surged by 85 bps to 46.1% in 2023, then sank by 801 bps to 415.23% in 2024, then jumped by 35 bps to 268.23% in 2025, then surged by 1960 bps to 4988.38% in 2026.
- Per Business Quant, the three latest IMCC Return on Capital Employed figures stand at 4988.38% (Q1 2026), 268.23% (Q4 2025), and 406.14% (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 8.52% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 27.36% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -1.50% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 21.43% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 0.46% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 20.04% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 5.24% |
| 10 | IM Cannabis | 591,792.44 | -193,562.09 | 1.03 Mn | 4,988.38% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4,988.38% |
| Dec 31, 2025 | -268.23% |
| Sep 30, 2025 | -406.14% |
| Jun 30, 2025 | -307.26% |
| Mar 31, 2025 | -1,442.93% |
| Dec 31, 2024 | -415.23% |
| Sep 30, 2024 | -522.39% |
| Jun 30, 2024 | -230.73% |
| Mar 31, 2024 | -123.12% |
| Dec 31, 2023 | -46.10% |
| Sep 30, 2023 | -135.70% |
| Jun 30, 2023 | -590.43% |
| Mar 31, 2023 | -560.65% |
| Dec 31, 2022 | -298.25% |
| Sep 30, 2022 | -133.42% |
| Jun 30, 2022 | -20.70% |
| Mar 31, 2022 | -13.36% |
| Dec 31, 2021 | -11.68% |
| Sep 30, 2021 | -18.65% |